医学
肝细胞癌
肿瘤科
新辅助治疗
内科学
靶向治疗
养生
中医药
重症监护医学
癌症
替代医学
病理
乳腺癌
出处
期刊:PubMed
日期:2023-12-01
卷期号:61 (12): 1035-1045
被引量:2
标识
DOI:10.3760/cma.j.cn112139-20230914-00121
摘要
Recurrence of hepatocellular carcinoma (HCC) after surgery is a major factor affecting the efficacy of the treatment of patients. Neoadjuvant treatment is an effective therapeutic method to reduce postoperative recurrence and prolong patient survival. However,there is no generally accepted neoadjuvant treatment regimen that has been proven to be effective so far. Recently,with the progress in systemic antitumor therapies,represented by targeted molecular agents and immune checkpoint inhibitors,and the improvement in local regional therapies,these treatment approaches have shown promising efficacy and safety in the field of neoadjuvant treatment for HCC. Under the organizational leadership of Committee of Digestive Surgery of Chinese Research Hospital Association and Committee of Liver Cancer of Chinese Anti-Cancer Association,Alliance of Chinese Expert Consensus on Neoadjuvant Therapy for Hepatocellular Carcinoma has discussed and revised several times and finally formulated the Chinese expert consensus on neoadjuvant therapy for hepatocellular carcinoma (2023 edition). This consensus aimed to review the Chinese characteristics of the diagnosis and treatment of HCC,to provide specific guidance and suggestions for preoperative treatment strategies for HCC,and further promote the management of the clinical pathway for neoadjuvant treatment of HCC.肝细胞癌(简称肝癌)术后复发是影响患者治疗效果改善的主要因素,新辅助治疗是降低术后复发、延长患者生存的有效治疗措施,但目前肝癌新辅助治疗尚无公认的有效方案。近年来,随着以靶向、免疫检测点抑制剂为代表的系统抗肿瘤药物的进步,以及肝癌局部治疗方法的改进,这些治疗方案在肝癌新辅助治疗领域有了初步有效的探索。肝癌新辅助治疗中国专家共识协作组在中国研究型医院学会消化外科专业委员会和中国抗癌协会肝癌专业委员会的组织领导下,经过多次讨论和修订,制定了《肝癌新辅助治疗中国专家共识(2023版)》,旨在结合中国肝癌诊疗特点,为术前肝癌治疗决策提供有针对性的指导性建议,同时进一步规范新辅助治疗的实施路径。.
科研通智能强力驱动
Strongly Powered by AbleSci AI